Material
Synthetic cyclic peptide analogue

Prepared for controlled laboratory studies involving melanocortin signaling models.
* Vial labels may use shortened names to keep the label legible. The full material and composition are stated in this profile.
Synthetic cyclic peptide analogue
Single peptide material.
Melanocortin receptor research.
PT-141 stands apart from peripheral vascular approaches because research centers on a centrally mediated melanocortin pathway involved in sexual-response signaling.
Central melanocortin signaling
Sexual desire, arousal, and associated distress
A source-led view of the findings reported to date, the maturity of the evidence, and the limits that matter when interpreting it.
Phase 3 trials of bremelanotide reported statistically significant but modest improvements in desire and related distress in the specific population studied. Nausea, flushing, and headache were more frequent than with placebo.
PT-141 is commonly used as a shorthand for bremelanotide, but clinical findings apply to the characterized trial drug, population, and formulation. They do not establish equivalence of a research vial.
This summary describes published research on the named material or its components. It does not establish safety, efficacy, equivalence, or suitability of this Veyvanta research product for human use.
Convert a declared vial amount and diluent volume into nominal concentration, liquid volume, and the equivalent position on a U-100 scale.
Enter a positive diluent volume and target amount to calculate.
This tool performs unit conversion only. It does not recommend an amount, frequency, route, diluent, handling method, or human use. Results assume ideal mixing and a U-100 scale of 100 units per mL; validated laboratory procedures and material-specific compatibility take priority.
This is the evergreen product profile. Enter the code from a physical vial to display its specific record.
Verify this vialThis QR code opens the current product profile with its associated vial record.